Oncology

Hero image

Phase I-III oncology expertise

We know that oncology drug development requires flexibility, determination and engaged study sites with close management. Trained in their therapeutic area and the specifics of your study protocol, our CRAs are regionally based, for a flexible, cost-effective and fully integrated approach.

Our experience in conducting Phase I/II adaptive oncology clinical trials, through to Phase III rescue studies has given us a deep understanding of managing complex hospital-based studies, supported by a world-leading oncology advisory board.

Your oncology study: from conception to delivery

Alain Thibault, Chairman of the Oncology Advisory Board

With 24 years of experience in oncology study delivery, our expertise enables us to successfully combine your business needs with those of the patients. Discover how.

Case Study 1

Case Study 1

First-in-human phase I study of the DNA repair inhibitor in combination with radiotherapy in patients with skin metastases from melanoma.

Read here

Case Study 2

Case Study 2

Phase III rescue study, in patients with locally recurrent or metastatic breast cancer.

Read here

Case Study 3

Case Study 3

First in patient study, in patients with relapsed/refractory Non-Hodgkin’s Lymphoma and relapsed/refractory CLL.

Read here

Oncology

Oncology webinar

If you missed our live ESMO Update: State of the Art in Early Phase Oncology Trial Design webinar you can view on demand now. The science looks promising and you have secured vital funding to take your compound to the clinical stage.

Watch now

Drug types

We have managed clinical trials with all products types including, vaccines, new chemical entities (NCEs), antisense therapy, small molecules, peptides, antibodies, genetically modified organisms (GMOs) and biologics, and gene therapy.

Let’s collaborate

If you think we could be right for you, get in touch.

Submit an RFI/RFP